Stemline Therapeutic (STML) Stock Price & Overview

NASDAQ:STML

Current stock price

11.83
-0.17 (-1.42%)
At close:
11.83
0 (0%)
After Hours:

The current stock price of STML is 11.83 null. Today STML is down by -1.42%. In the past month the price decreased by -2.75%. In the past year, price decreased by -16.51%.

STML Key Statistics

52-Week Range3.21 - 18.22
Current STML stock price positioned within its 52-week range.
1-Month Range11.69 - 12.24
Current STML stock price positioned within its 1-month range.
Market Cap
621.205M
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-1.59
Dividend Yield
N/A

STML Stock Performance

Today
-1.42%
1 Week
-0.92%
1 Month
-2.75%
3 Months
+161.15%
Longer-term
6 Months +17.71%
1 Year -16.51%
2 Years N/A
3 Years N/A
5 Years N/A
10 Years N/A

STML Stock Chart

Stemline Therapeutic / STML Daily stock chart

STML Technical Analysis

ChartMill assigns a technical rating of 7 / 10 to STML. When comparing the yearly performance of all stocks, STML is one of the better performing stocks in the market, outperforming 93.31% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating
STML Full Technical Analysis Report

STML Fundamental Analysis

ChartMill assigns a fundamental rating of 5 / 10 to STML. STML has a great financial health rating, but its profitability evaluates not so good.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
STML Full Fundamental Analysis Report

STML Earnings

Next Earnings DateN/A
Last Earnings DateN/A
STML Earnings History

STML Forecast & Estimates


Analysts
Analysts77.2
Price TargetN/A
EPS Next Y28.42%
Revenue Next YearN/A
STML Forecast & Estimates

STML Financial Highlights

Over the last trailing twelve months STML reported a non-GAAP Earnings per Share(EPS) of -1.59. The EPS increased by 47.7% compared to the year before.


Income Statements
Revenue(TTM)47.04M
Net Income(TTM)-70.70M
Industry RankSector Rank
PM (TTM) -150.3%
ROA -41.44%
ROE N/A
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%38.36%
Sales Q2Q%75.74%
EPS 1Y (TTM)47.7%
Revenue 1Y (TTM)747.8%
STML financials

STML Ownership

Ownership
Inst Owners75.8%
Shares52.51M
Float32.42M
Ins Owners0.45%
Short Float %N/A
Short RatioN/A
STML Ownership

About STML

Company Profile

Stemline Therapeutics, Inc. is a biopharmaceutical company developing oncology therapeutics that target cancer stem cells and tumor bulk. The company is developing SL-401, a biologic-drug conjugate, for relapsed or refractory acute myeloid leukemia; and SL-701, a synthetic peptide vaccine, for pediatric and adult high-grade gliomas. Stemline Therapeutics, Inc. is based in New York.

Company Info

Stemline Therapeutic

750 LEXINGTON AVENUE ELEVENTH FLOOR

NEW YORK NY 10022

CEO: Ivan Bergstein

Phone: 646-502-2311

Stemline Therapeutic / STML FAQ

What does Stemline Therapeutic do?

Stemline Therapeutics, Inc. is a biopharmaceutical company developing oncology therapeutics that target cancer stem cells and tumor bulk. The company is developing SL-401, a biologic-drug conjugate, for relapsed or refractory acute myeloid leukemia; and SL-701, a synthetic peptide vaccine, for pediatric and adult high-grade gliomas. Stemline Therapeutics, Inc. is based in New York.


Can you provide the latest stock price for Stemline Therapeutic?

The current stock price of STML is 11.83 null. The price decreased by -1.42% in the last trading session.


Does STML stock pay dividends?

STML does not pay a dividend.


How is the ChartMill rating for Stemline Therapeutic?

STML has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 5 out of 10.